Novo Nordisk's controlling shareholder plans to invest about $35 bln by 2030

Novo Holdings, the controlling shareholder of Danish obesity drugmaker Novo Nordisk (NOVOb.CO), opens new tab, plans to invest about $35 billion by 2030, CEO Kasim Kutay told Reuters in an interview on Monday.
Novo Holdings would invest about $5 billion a year in the next five years, and that could go up to $7 billion a year by 2030, Kutay said.